Regorafenib monotherapy as the later-line treatment for elderly patients with metastatic colorectal cancer: a multicenter real-world study
Regorafenib monotherapy was shown to be efficacious in the elderly population, but further evidence is needed for guidance. Based on our multicenter real-world investigation, the final daily dose was significantly associated with OS. For those aged <70 years, maintaining the final dose at 120 mg/day may have prognostic advantages. The suggested medication protocol requires validation through comprehensive clinical trials.
Authors
- Yongkun Sun (ORCID: https://orcid.org/0000-0003-3302-6023)
- Nan Zun Teo (ORCID: https://orcid.org/0000-0002-5475-476X)
- Caifeng Gong (ORCID: https://orcid.org/0000-0002-1864-8206)
- Zhichao Jiang (ORCID: https://orcid.org/0000-0003-0092-1494)
- Lin Yang (ORCID: https://orcid.org/0000-0002-5183-2101)
- Wen Zhang (ORCID: https://orcid.org/0000-0001-7808-9867)
- Yunbo Zhao
- Aiping Zhou (ORCID: https://orcid.org/0000-0003-1632-837X)
- Jinglong Huang (ORCID: https://orcid.org/0000-0002-9729-7079)
- Wang Qu
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Changi General Hospital (SG)
- Beijing Hospital (CN)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/jgo-24-464
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Zhengzhou University
- Chinese Academy of Medical Sciences
- China Medical University
- Hebei University
- Qingdao University
- Hebei Medical University
- Jiangsu Cancer Hospital